Accuray Incorporated (NASDAQ:ARAY) Short Interest Update

Accuray Incorporated (NASDAQ:ARAY) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 4,030,000 shares, a growth of 12.3% from the December 31st total of 3,590,000 shares. Based on an average trading volume of 624,600 shares, the short-interest ratio is currently 6.5 days.

Accuray Trading Down 0.4 %

Shares of Accuray stock traded down $0.01 during trading hours on Monday, hitting $2.22. The company’s stock had a trading volume of 232,837 shares, compared to its average volume of 610,648. The company has a market capitalization of $223.37 million, a PE ratio of -13.09 and a beta of 1.51. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. The stock has a 50 day moving average of $2.08 and a 200 day moving average of $1.96. Accuray has a 12 month low of $1.40 and a 12 month high of $2.95.

Accuray (NASDAQ:ARAY) last posted its earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. The business had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. During the same period in the prior year, the business earned ($0.03) EPS. Analysts predict that Accuray will post 0.01 earnings per share for the current year.

Analysts Set New Price Targets

Separately, StockNews.com downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research note on Friday, November 15th.

Institutional Investors Weigh In On Accuray

Several institutional investors have recently added to or reduced their stakes in ARAY. Foundry Partners LLC raised its stake in shares of Accuray by 51.3% in the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock valued at $3,937,000 after purchasing an additional 741,900 shares during the period. State Street Corp raised its position in Accuray by 3.8% in the 3rd quarter. State Street Corp now owns 1,894,287 shares of the medical equipment provider’s stock valued at $3,410,000 after buying an additional 70,008 shares during the last quarter. Barclays PLC lifted its stake in Accuray by 97.9% in the 3rd quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock valued at $380,000 after acquiring an additional 104,310 shares in the last quarter. BNP Paribas Financial Markets boosted its position in Accuray by 1,650.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 146,384 shares of the medical equipment provider’s stock worth $263,000 after acquiring an additional 138,022 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Accuray by 489.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after acquiring an additional 230,695 shares in the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.